OmniAb
Antibody discovery company.
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 Valuation: €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 Valuation: €0.0 14.4x EV/Revenue -65.3x EV/EBITDA | round | |
| investor | €0.0 Valuation: €0.0 14.4x EV/Revenue -65.3x EV/EBITDA | round | |
* | N/A | N/A | Post IPO Equity |
| Total Funding | 000k | ||
Ligand Pharmaceuticals(exited)
Avista Healthcare Partners(exited)
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 49 % | 70 % | (42 %) | (23 %) | (18 %) | 45 % | 50 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (52 %) | (22 %) | (146 %) | (193 %) | (198 %) | (105 %) | (75 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (78 %) | (38 %) | (148 %) | (235 %) | (292 %) | (168 %) | (100 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 113 % | 82 % | 165 % | 209 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Notes (0)
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
